Related Experiment Video
Updated: May 12, 2025
08:17
Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy
Published on: June 7, 2015
15.5K
Phase 2 Trial of Stereotactic Body Radiation Therapy with Dose Escalation Using Simultaneous Integrated Boost for
Takamasa Mitsuyoshi1, Peter J K Tokuda1,2, Yumi Kokubo1
1Department of Radiation Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
Advances in Radiation Oncology
|May 9, 2025
Summary
Dose-escalated simultaneous integrated boost SBRT (SIB-SBRT) for spinal metastases shows high local control rates. This advanced radiation technique offers excellent outcomes with manageable side effects.
Area of Science:
- Oncology
- Radiation Oncology
- Medical Physics
Background:
- Stereotactic body radiation therapy (SBRT) is a standard treatment for spinal metastases.
- Local recurrence remains a challenge despite effective SBRT.
- Optimizing SBRT techniques is crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy of dose-escalated SBRT using simultaneous integrated boost (SIB-SBRT) for spinal metastases.
- To assess if SIB-SBRT can improve local control (LC) compared to standard SBRT.
- To determine the safety profile of SIB-SBRT, focusing on adverse events (AEs).
Main Methods:
- Prospective phase 2 clinical trial involving patients with spinal metastases.
- SIB-SBRT delivered in 5 fractions over 1 week.
- Dose prescription: 30 Gy to planning target volume, 40-45 Gy to gross tumor volume via SIB.
- Regular clinical and imaging follow-up to assess LC and AEs, including vertebral compression fractures (VCFs).
Main Results:
- 1- and 2-year local control rates of 100.0% and 95.0%, respectively.
- Only 1 case of local recurrence observed at 18 months.
- 1- and 2-year overall survival rates of 92.0% and 72.8%.
- Low incidence of vertebral compression fractures (VCFs) and no radiation myelopathy.
Conclusions:
- Dose-escalated SIB-SBRT is highly effective for achieving local control in spinal metastases.
- The technique demonstrates an acceptable toxicity profile.
- Results support further investigation in larger comparative trials.
